Publications by authors named "O E Bechter"
Purpose: To investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year data of 935 responder and non-responder patients at various time points after treatment initiation in CheckMate 069, 066, and 067 studies.
Patients And Methods: Treatment-naive advanced melanoma patients received nivolumab+ipilimumab or nivolumab monotherapy. To decrease immortal time bias, 3-, 6-, or 12-month overall survival (OS) and progression-free survival (PFS) landmark analyses were performed.
Article Synopsis
- Transitioning from a proliferative to an invasive melanoma phenotype increases vulnerability to ferroptosis, but the regulatory circuits behind this susceptibility are unclear.
- Apolipoprotein E (ApoE) was identified as a key lipid-metabolism gene that helps differentiate between ferroptosis-resistant and sensitive melanoma states by protecting invasive cells from ferroptosis-inducing agents.
- The study suggests that ApoE secretion and its expression may serve as potential biomarkers for poor response to ferroptosis in melanoma patients.
Background: Genetic variants of UGT1A1, involved in glucuronidation and clearance of bilirubin, are associated with reduced bilirubin metabolization and drug-induced isolated hyperbilirubinemia. We studied the impact of the UGT1A1*28 polymorphism on drug-induced isolated hyperbilirubinemia in metastatic renal cell carcinoma patients treated with pazopanib, cabozantinib, and axitinib.
Methods: We genotyped the UGT1A1*28 TA6/TA6-TA6/TA7-TA7/TA7 polymorphism and correlated with median baseline, on-treatment and peak bilirubin levels during therapy, incidence of grade-1- or -2 (G1/2)-hyperbilirubinemia and time-to-G1-hyperbilirubinemia.
Article Synopsis
- The study assessed health-related quality of life (HRQoL) in 84 patients with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab.
- Patients received cemiplimab every 3 weeks for up to 9 cycles, and HRQoL was evaluated using the QLQ-C30 and Skindex-16 questionnaires at various points.
- Results showed that 62-90% of patients experienced improvement or maintenance in HRQoL, except for fatigue, which remained a concern throughout the treatment.
Article Synopsis
- The study investigates the impact of high-dose vitamin D supplementation on melanoma relapse in patients who have had curatively resected cutaneous melanoma (CM).* -
- A total of 436 patients were randomly assigned to either a vitamin D treatment group, receiving 100,000 IU monthly, or a placebo group, with follow-up lasting up to 116 months.* -
- Results showed that while vitamin D supplementation significantly increased serum levels, it did not noticeably improve relapse-free survival or reduce melanoma-related deaths compared to the placebo group.*